Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients: A pilot trial

Minerva Medica

Volumn 96, Issue 5, 2005, Pages 365-371

  Campo, C ^a   Saavedra, J ^a   Segura, J ^a   Roldan C ^a   Ruilope, L M ^a   Parati, G ^b,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Antihypertensive agents; Arterial hypertension; Calcium antagonists; Left ventricular mass; Smoothness index; Trough to peak ratio

Indexed keywords

HYDROCHLOROTHIAZIDE; LERCANIDIPINE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; OPEN STUDY; PILOT STUDY; PROSPECTIVE STUDY; SMOOTHNESS INDEX; TROUGH TO PEAK RATIO; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 28544446198     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Meredith PA, Elliot HL. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive patients. J Cardiovasc Pharmacol 1994;23 Suppl 5:526-30.
2. Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of trough-to-peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995;13:1105-12.
3. Omboni S, Parati G, Mancia G. The trough peak ratio and the smoothness index in the evaluation of control of 24 h blood pressure by treatment in hypertension. Blood Press Monit 1998;3:201-4.
4. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998;16:1685-91.
5. Parati G, Omboni S, Mancia G. [Trough-peak ratio and the smoothness index in the assessment of duration and homogeneity of 24-hour antihypertensive effect]. Cardiologia 1999;44 Suppl 1 (Pt 1):345-8. Italian.
6. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R et al., for the SAMPLE study group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997;95: 1464-70.
7. Rizzoni D, Muiesan ML, Salvetti M, Castellano M, Bettoni G, Monteduro C et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001;19:703-11.
8. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F et al. ELSA Investigators. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001;19:1981-9.
9. Mancia G, Parati G. Importance of smooth and sustained blood pressure control in preventing cardiovascular morbidity and mortality. Blood Press 2001;3 Suppl 3:26-32.
10. Mancia G, Omboid S, Zanchetd A. Clinical advantages of lipophile dihydropydines. Blood Press 1998;7 Suppl 2:23-6.
11. McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000;60:123-40.
12. Omboni S, Zanchetd A. On behalf of the Multicenter Study Investigators: Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998;16:1831-8.
13. Stergiou GS, Efstathiou SP, Skeva II, Baibas NM, Roussias LG, Mountokalakis TD. Comparison of the smoothness index, the trough: peak ratio and the morning: evening ratio in assessing the features of the antihypertensive drug effect. J Hypertens 2003;2:913-20.
14. 1999. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Hypertension 1999;17:151-83.
15. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977;55:450-8.
16. Leonetti G, Magnani B, Pessina A, Rappelli A, Trimarco B, Zanchetti A on behalf of the cohort study group. Tolerability of long-term treatment with lercanidipine vs amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-40.
17. De Giorgo LA, Orlandini F, Malasom P. Doubleblind cross-over study of lercanidipine in the treatment of milto-moderate essential hypertension. Curr Ther Res Clin Exp 1999;60:511-20.
18. Serravalle G. Comparative effects of lercanidipine and hydrochlorotiazide on hypertension-related cardiac and vascular structural alterations. Am J Hypertens 2002;15 Suppl 1:A39.
19. Macia G, Omboni S, Parati G. The importance of blood pressure variability in hypertension. Blood Pressure Monitoring 2000;5 Suppl 1:89-15.
20. Donnelly R, Elliott HL, Meredith PA, Kelman AW, Reid JL. Nifedipine: individual responses and concentration-effect relationships. Hypertension 1988;12:443-9.